![]() Desprez 3ġLaboratory of Hematology, Emile Muller Hospital, Mulhouse 2Laboratory of Hematology 3CRTH Strasbourg 4Hospital Pharmacy 5Pain Assessment and Treatment Center, Strasbourg Hospital, Strasbourg, France P002 Ways to fight against pain related to hemophilic Arthropathy: Experiment in Strasbourg hospitalĪ. The multivariable analyses are currently being performed and the results will be presented at the conference.ĭiscussion/Conclusion: Our preliminary findings suggest that patient and treatment related factors are associated with inhibitor development after 50 EDs in patients with NSHA.ĭisclosure of Interest: None declared. Furthermore, the time interval in which the last 10 EDs were received was shorter in cases (30 days, IQR 9-384) than in controls (202 days, IQR 23-620). In the last 10 EDs, mean FVIII dose was higher in cases (35 IU/kg, IQR 20-45) than in controls (25 IU/kg, IQR 18-35). At last treatment, plasma-derived FVIII was the most used product type in both groups: 63% in cases and 55% in controls. At first treatment, cases were older (35 years, IQR 12-49) than controls (18 years, IQR 8.5-37). Median FVIII baseline level was comparable for cases (6.0, IQR 4.0-10.0) and controls (6.0, IQR 3.0-12.0). Arg2150His was the most prevalent F8 mutation in cases (19%) and controls (7%). Treatment related factors were available in 24 cases and 73 controls. Of all patients, patient related factors were available. Results: In total, 31 cases and 84 controls were included. We performed conditional logistic regression on the matched groups to analyze the association between patient and treatment related determinants and inhibitor development, adjusted for predefined confounders. Patient and treatment related factors were compared between cases and controls. Clinical data of the first ED and the last 30 EDs were collected until inhibitor development in cases and up to the same number of EDs in controls. Matching was based on date of birth, number of EDs and center/country. Methods: In this nested case-control study, we selected all patients with inhibitor development after 50 EDs (cases) and matched inhibitor-negative patients (controls) from the INSIGHT cohort, including 2709 NSHA patients (FVIII level 2-40 IU/dL). The aim of this study is to identify patient and treatment related factors associated with late onset inhibitor development in NSHA patients with more than 50 EDs. In contrast to severe patients, in whom the risk to develop an inhibitor decreases after 50 exposure days (EDs), NSHA patients have a lifelong inhibitor risk. ![]() ![]() Introduction: Inhibitor development is a major complication of factor VIII (FVIII) treatment in non-severe hemophilia A (NSHA). Fijnvandraat 1, on behalf of INSIGHT Study GroupġDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Amsterdam UMC, location AMC 2Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, location AMC, Amsterdam 3Department of Paediatric Haematology, Erasmus Medical Center-Sophia Children's hospital, Rotterdam 4Van Creveldkliniek, University Medical Center Utrecht, Utrecht 5Department of Hematology, Radboud University Medical Center, Radboud University, Nijmegen, Netherlands 6Fondazione IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan 7Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Parma 8Universita’ Roma La Sapienza, Policlinico Umberto I, Rome, Italy 9Department of Hematology and Vascular Diseases, Skåne University Hospital, Malmö 10Coagulation Unit, Haematology Centre, Karolinska University Hospital, Stockholm, Sweden 11Department of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn 12HZRM-Haemophilia Centre Rhein Main, Frankfurt-Mörfelden, Germany 13Department of Hematology, La Paz University Hospital-IdiPaz, Madrid 14University Hospital la Fe, Valencia, Spain 15Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands P001 Patient and treatment related factors and inhibitor development after 50 exposure days in patients with non-severe hemophilia A-preliminary data of a nested case-control studyĪ. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |